Duarte started at Charlesbank as a principal in September, based out of New York, his LinkedIn profile shows.
The investor joined Charlesbank after more than seven years at Advent, most recently as a principal in the New York office, where he focused on buyouts in the healthcare sector. Duarte got his start in private equity as an analyst at Audax Group, and then spent about two years as an associate at Hellman & Friedman investing in industrial and software businesses.
Duarte joins key team members focused on healthcare at Charlesbank, including managing directors Joshua Beer, Joshua Klevens and Brandon White, as well as principal Neal Dignum. Nicholas Rolfes and Danielle Cosentino are vice presidents on the healthcare team.
Charlesbank’s current umbrella of healthcare investments include MB2Dental, MyEyeDoctor and Tecomet. In healthcare technology, its portfolio includes Symplr and Healthcare Fraud Shield.
The private equity firm’s latest flagship PE fund, Charlesbank Equity Fund X, closed on its hard cap of $3.75 billion in February, less than six months after launch. Concurrently, it closed on an $800 million companion vehicle, Charlesbank Equity Fund X Overage Fund, which enables Fund X to expand its opportunity set to include attractive investments requiring larger amounts of capital.
Fund X targets investments in mid-market companies with enterprise values ranging from $150 million to $3 billion, with the flexibility to deploy up to $500 million per transaction.
Charlesbank, formed in 1998 by five veterans of Harvard Management Company‘s private equity group, has offices in Boston and New York. The firm focuses on management-led buyouts and growth capital financing, as well as opportunistic credit and technology investments. It seeks to build companies with sustainable competitive advantage and excellent prospects for growth.
Charlesbank and Duarte did not immediately return requests for comment.